seekingalpha.com
Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript
Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript
NeoGenomics, Inc.NEONASDAQ
Loading
Latest News
Loading news...
businesswire.com
SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."
IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that its specialized aesthetic brand, “NEO Skin Clinic,” will open its flagship location in Tokyo's Ginza district, a globally recognized medical tourism hub and highly competitive district, on Saturday, March 28, 2026. The Ginza flagship, located i.
businesswire.com
NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
globenewswire.com
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET.
businesswire.com
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
businesswire.com
Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology.
defenseworld.net
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Hold” from Brokerages
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have been assigned an average rating of "Hold" from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, five have given a buy recommendation and
zacks.com
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
businesswire.com
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
seekingalpha.com
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
zacks.com
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.
businesswire.com
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.
zacks.com
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.
businesswire.com
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.
defenseworld.net
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of “Hold” by Analysts
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, five have given a buy recommendation and one has given
businesswire.com
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.
seekingalpha.com
NeoGenomics: Distribution Moat In Community Oncology
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.
defenseworld.net
Campbell & CO Investment Adviser LLC Has $235,000 Stock Holdings in NeoGenomics, Inc. $NEO
Campbell and CO Investment Adviser LLC lowered its position in NeoGenomics, Inc. (NASDAQ: NEO) by 60.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,487 shares of the medical research company's stock after selling 46,288 shares during
businesswire.com
Better Marks One-Year Partnership with NEO Home Loans — NEO Loan Officers See 91% Growth in Funded Loans 6 Months After Implementing Tinman® AI Platform
NEW YORK--(BUSINESS WIRE)---- $BETR #AI--Better Home & Finance Holding Company (NASDAQ: BETR) (“Better.com”), the leading AI-native home finance company and the first fintech to fund more than $100 billion in loan volume, celebrates the one-year anniversary of its partnership with NEO Home Loans (“NEO”) and proudly announces significant gains in production efficiency and cost to originate through its advisor-led distributed retail channel, NEO powered by Better. This monumental growth demonstrates the me.
defenseworld.net
Comparing AstraZeneca (NASDAQ:AZN) and NeoGenomics (NASDAQ:NEO)
NeoGenomics (NASDAQ: NEO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Insider and Institutional Ownership 98.5% of NeoGenomics shares are held